|
Post by sayhey24 on Feb 13, 2017 6:17:06 GMT -5
Welcome to Mannkind, I am very excited to have you on our team as our hopes and future are now in your hands. Afrezza is the greatest advance in diabetes treatment since Banting and Best first used insulin in 1922, 95 years ago. You have the ability to dramatically affect the future in diabetes treatment. Research teams are currently working on methods to reduce A1c from the 9+'s to the 7's. With afrezza it should be the norm for patients to be in the 6's, 5's and even 4's. If the patients are not hitting these numbers, don't blame the product as they are either dosing improperly, holding the inhaler upside down, or the patient has other issues in addition to their diabetes.
There is only one thing which can bring down high blood sugar and it is insulin. The best insulin which does this is the insulin secreted from the pancreas, monomer human insulin. No pills, DPP-4 Inhibitor, GLP-1 Agonist, SGLT-2 Inhibitor, or any Analog insulin can do what the healthy pancreas can do. If you can NOT sell afrezza don't blame the product as the product is this exact same insulin which the pancreas secretes. No other product can do what afrezza does and has the pharmakinetics afrezza does which mimics the pancreas. No other Analog is as easy to use as afrezza and there is no carb counting. If sold properly afrezza should dominate the entire diabetes space and should be used by most T1's and T2's including off label for corrections for smokers and those with COPD.
It will not be easy as Big Pharma has been and will continue to throw everything at you to stop you and afrezza. They will convince doctors its too new BUT you know its human insulin and human insulin has been around since the beginning of man. You will also be armed with all the info on FDKP.
BP will point the doctors to the lackluster A1c results from Studies 171 and 175 but you will be armed with the study results from that one doctor in those studies called out by the FDA because he had his patients follow the 90 minute second dose as outlined in the protocol to mimic phase 2 pancreatic release and his results blew away the Insulin Aspart results. You will explain how afrezza mimics the healthy pancreas with phase1 and phase 2 insulin release. You will also explain how import each phase is and that only afrezza can provide that ALL important phase 1 release. You will also be armed with the clamp study results and explain why A1c is really not the best way to treat diabetes but rather time in range.
They will then tell you the current protocol for T2's is to first treat will pills but you will have all the latest studies which show how early insulin intervention can not only stop the progression their patients will see on those pills but in some cases reverse diabetes. For early insulin intervention there is no better choice than afrezza.
Once they run out of every other excuse they will throw the cancer Red Herring at you but since you already know human insulin does not cause cancer you will smile. You will then explain that current diabetics do have a higher rate of cancer and you will be armed with the studies which point to the elongated amount of time the current analogs are in the system as one potential for increased cancer rates. You will explain how fast afrezza is in and out so this may give afrezza a big advantage for not promoting cancer as other analogs may do. You will also have the AspB10 report and explain that no one is quite sure of the long term effects with the analogs and work is just starting to understand if the analogs may be a reason for the higher incidents. Yes, we have been told they are safe but are they really safe for everyone? We know human insulin is safe.
You will be armed with your Abbott Libre and Dexcom and explain titrating using the guide in the starter kit and explain why glucose measuring several times after eating is needed and a second and maybe even a third dose of afrezza may be needed after meals to mimic the pancreas phase 2 release. You can then explain the Libre is fully covered and by lending the new T2 a scanner for several months to do the home measurements while returning every two weeks to collect and review the measurements it is not only the best way to titrate but also fully covered for the patient and profitable for the doctor. It will also guarantee the measurements are available and correct. Ideally Mannkind will have software which can model these results and highlight adjustments which can be made to dosing.
Do your homework, be prepared and be persistent. You have one of the biggest $ markets to sell into and you have the best product. You have the potential to have hundreds of $millions in sales within a few short years. You have never had such a sales opportunity as this. You have real users showing real results on youtube which researchers still can't mimic in their labs with non-insulin approaches. As additional technology products which measure and track real time glucose levels enter the market this should make selling afrezza even easier because nothing can control high blood sugar like afrezza except a healthy pancreas.
|
|
|
Post by silentknight on Feb 13, 2017 6:49:14 GMT -5
Interesting points and all valid, but I'm worried that sales team members will be limited on what they can and cannot claim by the label. If so, that would make most of your points moot.
However, despite that, I believe a sales person worth their salt will find a way to tiptoe around those restrictions and convince doctors to write scripts. I wish them luck. This will be Afrezza's last chance to survive with Mannkind.
|
|
|
Post by buyitonsale on Feb 13, 2017 10:49:48 GMT -5
This is the first attempt to promote Afrezza using Mannkind's own sales force. It's not the last of anything. Mannkind has been around through many obstacles and it's here to stay.
|
|
|
Post by peppy on Feb 13, 2017 11:01:12 GMT -5
Welcome to Mannkind, I am very excited to have you on our team as our hopes and future are now in your hands. Afrezza is the greatest advance in diabetes treatment since Banting and Best first used insulin in 1922, 95 years ago. You have the ability to dramatically affect the future in diabetes treatment. Research teams are currently working on methods to reduce A1c from the 9+'s to the 7's. With afrezza it should be the norm for patients to be in the 6's, 5's and even 4's. If the patients are not hitting these numbers, don't blame the product as they are either dosing improperly, holding the inhaler upside down, or the patient has other issues in addition to their diabetes. There is only one thing which can bring down high blood sugar and it is insulin. The best insulin which does this is the insulin secreted from the pancreas, monomer human insulin. No pills, DPP-4 Inhibitor, GLP-1 Agonist, SGLT-2 Inhibitor, or any Analog insulin can do what the healthy pancreas can do. If you can NOT sell afrezza don't blame the product as the product is this exact same insulin which the pancreas secretes. No other product can do what afrezza does and has the pharmakinetics afrezza does which mimics the pancreas. No other Analog is as easy to use as afrezza and there is no carb counting. If sold properly afrezza should dominate the entire diabetes space and should be used by most T1's and T2's including off label for corrections for smokers and those with COPD. It will not be easy as Big Pharma has been and will continue to throw everything at you to stop you and afrezza. They will convince doctors its too new BUT you know its human insulin and human insulin has been around since the beginning of man. You will also be armed with all the info on FDKP. BP will point the doctors to the lackluster A1c results from Studies 171 and 175 but you will be armed with the study results from that one doctor in those studies called out by the FDA because he had his patients follow the 90 minute second dose as outlined in the protocol to mimic phase 2 pancreatic release and his results blew away the Insulin Aspart results. You will explain how afrezza mimics the healthy pancreas with phase1 and phase 2 insulin release. You will also explain how import each phase is and that only afrezza can provide that ALL important phase 1 release. You will also be armed with the clamp study results and explain why A1c is really not the best way to treat diabetes but rather time in range. They will then tell you the current protocol for T2's is to first treat will pills but you will have all the latest studies which show how early insulin intervention can not only stop the progression their patients will see on those pills but in some cases reverse diabetes. For early insulin intervention there is no better choice than afrezza. Once they run out of every other excuse they will throw the cancer Red Herring at you but since you already know human insulin does not cause cancer you will smile. You will then explain that current diabetics do have a higher rate of cancer and you will be armed with the studies which point to the elongated amount of time the current analogs are in the system as one potential for increased cancer rates. You will explain how fast afrezza is in and out so this may give afrezza a big advantage for not promoting cancer as other analogs may do. You will also have the AspB10 report and explain that no one is quite sure of the long term effects with the analogs and work is just starting to understand if the analogs may be a reason for the higher incidents. Yes, we have been told they are safe but are they really safe for everyone? We know human insulin is safe. You will be armed with your Abbott Libre and Dexcom and explain titrating using the guide in the starter kit and explain why glucose measuring several times after eating is needed and a second and maybe even a third dose of afrezza may be needed after meals to mimic the pancreas phase 2 release. You can then explain the Libre is fully covered and by lending the new T2 a scanner for several months to do the home measurements while returning every two weeks to collect and review the measurements it is not only the best way to titrate but also fully covered for the patient and profitable for the doctor. It will also guarantee the measurements are available and correct. Ideally Mannkind will have software which can model these results and highlight adjustments which can be made to dosing. Do your homework, be prepared and be persistent. You have one of the biggest $ markets to sell into and you have the best product. You have the potential to have hundreds of $millions in sales within a few short years. You have never had such a sales opportunity as this. You have real users showing real results on youtube which researchers still can't mimic in their labs with non-insulin approaches. As additional technology products which measure and track real time glucose levels enter the market this should make selling afrezza even easier because nothing can control high blood sugar like afrezza except a healthy pancreas. Quote: they will throw the cancer Red Herring at you but since you already know human insulin does not cause cancer you will smile. You will then explain that current diabetics do have a higher rate of cancer and you will be armed with the studies which point to the elongated amount of time the current analogs are in the system as one potential for increased cancer rates. You will explain how fast afrezza is in and out so this may give afrezza a big advantage for not promoting cancer as other analogs may do.
Reply: Good one. Physicians have been hearing for years that glucose feeds cancer cells. and the capillary systems that grow around the cancers.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 13, 2017 11:34:18 GMT -5
I'm disturbed by comments regarding glucose and cancer: all cells utilize glucose as their primary energy source; so if one believes glucose causes cancer then all cells should become cancerous?
|
|
|
Post by afrezzamiracle on Feb 13, 2017 11:36:22 GMT -5
JUST SELL BABY!!!
|
|
|
Post by peppy on Feb 13, 2017 11:38:45 GMT -5
I'm disturbed by comments regarding glucose and cancer: all cells utilize glucose as their primary energy source; so if one believes glucose causes cancer then all cells should become cancerous? true. cancer cells have been shown to utilize more glucose. (all that growing being done?) Cancer, tumors grow their own blood supply vessels, co-lateral circulation.
More fuel for the fire? That is why some people change their diets to more vegan based after diagnosis. Some just take the tx and keep on keeping on.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 13, 2017 11:45:00 GMT -5
So then a diabetic, due to insulin issue has more glucose floating around in their system not being used as fuel for cells vs a person without diabetes having the glucose absorbed into cells as fuel. Not a scientist as my comments indicate but does insulin allow glucose into cancer cells as well as healthy cells?
|
|
|
Post by peppy on Feb 13, 2017 12:00:45 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 13, 2017 12:13:03 GMT -5
peppy "cancer cells have been shown to utilize more glucose. (all that growing being done?) Cancer, tumors grow their own blood supply vessels, co-lateral circulation." The reason cancer cells require greater glucose and blood vessels than non-cancerous cells is because of their rapid growth. Glucose is not the cause of cancer origination.
|
|
|
Post by silentknight on Feb 13, 2017 12:58:19 GMT -5
This is the first attempt to promote Afrezza using Mannkind's own sales force. It's not the last of anything. Mannkind has been around through many obstacles and it's here to stay. This is MNKD 3.0. If this doesn't work, how long do they continue until they decide that despite its efficacy, the market for the product just might not be there? Do they launch MNKD 4.0, 5.0. 6.0? Trial and error indefinitely, at the expense of millions of dollars and more shareholder deficit? If MNKD can't market the drug with their own sales force, common sense tells you that they can't market the drug at all. If 3.0 fails, they will likely try to sell the product or company outright. Successful companies don't operate at a loss indefinitely and expect to keep stringing shareholders along. People may not like to believe it, but this is Afrezza greatest, and likely last chance for success under MNKD, especially given financial runway and past experience. Those are working against MNKD here, not for them.
|
|
|
Post by johntherancher on Feb 13, 2017 12:59:06 GMT -5
A well written letter sayhey, and I wouldn't remove any part of it. I would like to add one thing to help prepare the sales reps. In my experience, there is a very vocal and strong concern about putting any material into diabetics' lungs over a long period of time. And, usually, diabetics are committing to a long course of treatment when they begin treatment of their disease. This concern isn't about the comparison of human insulin versus RAAs. It is a fear of developing cancer due to the continued use over time. To counter this concern as much as can be done, the sales reps should be armed with as much information about numbers of people having used Afrezza for how long and with comparisons to groups such as diabetics and non-diabetics and their incidences of cancer.
Again, this has been my experience when I recommended Afrezza to my diabetic brother who has a morbid concern about introducing insulin, even human insulin, into his lungs. My immediate and extended family has a number of diabetics at a variety of stages and he has some influence. It is difficult to counter this concern without a ready source of data and that is why I recommend creating a growing database of information that we can use to help convince reluctant diabetics. The database should be kept current as we add users but it is not, IMO, a large undertaking.
|
|
|
Post by peppy on Feb 13, 2017 13:13:45 GMT -5
A well written letter sayhey, and I wouldn't remove any part of it. I would like to add one thing to help prepare the sales reps. In my experience, there is a very vocal and strong concern about putting any material into diabetics' lungs over a long period of time. And, usually, diabetics are committing to a long course of treatment when they begin treatment of their disease. This concern isn't about the comparison of human insulin versus RAAs. It is a fear of developing cancer due to the continued use over time. To counter this concern as much as can be done, the sales reps should be armed with as much information about numbers of people having used Afrezza for how long and with comparisons to groups such as diabetics and non-diabetics and their incidences of cancer. Again, this has been my experience when I recommended Afrezza to my diabetic brother who has a morbid concern about introducing insulin, even human insulin, into his lungs. My immediate and extended family has a number of diabetics at a variety of stages and he has some influence. It is difficult to counter this concern without a ready source of data and that is why I recommend creating a growing database of information that we can use to help convince reluctant diabetics. The database should be kept current as we add users but it is not, IMO, a large undertaking. all that. I think it comes down to how you want to live. If you have to take fast acting insulin because you are type one, Do you want to eat, go high and then low? Are you wearing a pump? Do you have more fear of inhaling insulin than fear of managing fast acting subq? The mood swings.... the highs and lows. I personally would not fear inhaling afrezza. Molly used to say to me, "I am not going to live that long, I want to live happy." Died of a heart attack at 44. Are your family members helping to manage the carbohydrates by eating more meat/fat? Afrezza survives and people have a choice. We are all going to die. How do we want to live.
|
|
|
Post by johntherancher on Feb 13, 2017 13:40:52 GMT -5
I agree with you Peppy. And how I would live, if I were diabetic, which I am not, would be on Afrezza. But my older brother is precise and follows multiple daily injections with organized precision. He is also stubbornly in a groove and his doctor is old school, IMO. My younger brother died of what I think was a diabetic coma at age 56. His trip to Vietnam did not help him health wise. My mother took injections and monitored her glucose before she passed at age 89. Others in my family are taking injections for type 1 or type 2 diabetes. And no one has tried Afrezza, as far as I know.
An aside: I have enjoyed your "peppy" posts longer than I have been a member. Thank you for that. John
|
|
|
Post by dreamboatcruise on Feb 13, 2017 13:42:17 GMT -5
Welcome to Mannkind, I am very excited to have you on our team as our hopes and future are now in your hands. Afrezza is the greatest advance in diabetes treatment since Banting and Best first used insulin in 1922, 95 years ago. You have the ability to dramatically affect the future in diabetes treatment. Research teams are currently working on methods to reduce A1c from the 9+'s to the 7's. With afrezza it should be the norm for patients to be in the 6's, 5's and even 4's. If the patients are not hitting these numbers, don't blame the product as they are either dosing improperly, holding the inhaler upside down, or the patient has other issues in addition to their diabetes. There is only one thing which can bring down high blood sugar and it is insulin. The best insulin which does this is the insulin secreted from the pancreas, monomer human insulin. No pills, DPP-4 Inhibitor, GLP-1 Agonist, SGLT-2 Inhibitor, or any Analog insulin can do what the healthy pancreas can do. If you can NOT sell afrezza don't blame the product as the product is this exact same insulin which the pancreas secretes. No other product can do what afrezza does and has the pharmakinetics afrezza does which mimics the pancreas. No other Analog is as easy to use as afrezza and there is no carb counting. If sold properly afrezza should dominate the entire diabetes space and should be used by most T1's and T2's including off label for corrections for smokers and those with COPD. It will not be easy as Big Pharma has been and will continue to throw everything at you to stop you and afrezza. They will convince doctors its too new BUT you know its human insulin and human insulin has been around since the beginning of man. You will also be armed with all the info on FDKP. BP will point the doctors to the lackluster A1c results from Studies 171 and 175 but you will be armed with the study results from that one doctor in those studies called out by the FDA because he had his patients follow the 90 minute second dose as outlined in the protocol to mimic phase 2 pancreatic release and his results blew away the Insulin Aspart results. You will explain how afrezza mimics the healthy pancreas with phase1 and phase 2 insulin release. You will also explain how import each phase is and that only afrezza can provide that ALL important phase 1 release. You will also be armed with the clamp study results and explain why A1c is really not the best way to treat diabetes but rather time in range. They will then tell you the current protocol for T2's is to first treat will pills but you will have all the latest studies which show how early insulin intervention can not only stop the progression their patients will see on those pills but in some cases reverse diabetes. For early insulin intervention there is no better choice than afrezza. Once they run out of every other excuse they will throw the cancer Red Herring at you but since you already know human insulin does not cause cancer you will smile. You will then explain that current diabetics do have a higher rate of cancer and you will be armed with the studies which point to the elongated amount of time the current analogs are in the system as one potential for increased cancer rates. You will explain how fast afrezza is in and out so this may give afrezza a big advantage for not promoting cancer as other analogs may do. You will also have the AspB10 report and explain that no one is quite sure of the long term effects with the analogs and work is just starting to understand if the analogs may be a reason for the higher incidents. Yes, we have been told they are safe but are they really safe for everyone? We know human insulin is safe. You will be armed with your Abbott Libre and Dexcom and explain titrating using the guide in the starter kit and explain why glucose measuring several times after eating is needed and a second and maybe even a third dose of afrezza may be needed after meals to mimic the pancreas phase 2 release. You can then explain the Libre is fully covered and by lending the new T2 a scanner for several months to do the home measurements while returning every two weeks to collect and review the measurements it is not only the best way to titrate but also fully covered for the patient and profitable for the doctor. It will also guarantee the measurements are available and correct. Ideally Mannkind will have software which can model these results and highlight adjustments which can be made to dosing. Do your homework, be prepared and be persistent. You have one of the biggest $ markets to sell into and you have the best product. You have the potential to have hundreds of $millions in sales within a few short years. You have never had such a sales opportunity as this. You have real users showing real results on youtube which researchers still can't mimic in their labs with non-insulin approaches. As additional technology products which measure and track real time glucose levels enter the market this should make selling afrezza even easier because nothing can control high blood sugar like afrezza except a healthy pancreas. Many of these things you suggest are getting out of the bounds of what is allowed by FDA. Sales people cannot market for off-label. Many drug companies get nailed for that. We cannot afford the fines nor antagonizing an FDA from whom we need to get label change and approval of needed future trial protocols. I believe sales people can provide medical literature to docs but they cannot put spin on it as you suggest. I was once in a doc office and overheard an interaction between drug sales rep and doc... it was basically to say if he was interested in some of the scientific lit the rep would have one of the pharmas scientists/docs call. Pharmas have to be careful non physician sales reps aren't playing doctor/researcher and inappropriately using scientific lit as sales prop in a way that isn't supported in the conclusions of the paper. The Libre that allows patients to see readings isn't even approved in the US. I highly doubt doctors would purchase unapproved devices and loan to patients. As far as we know MNKD isn't even working on dosing software. Further, if they were it would still be years away from coming to market. Any software that suggests dosing would need to go through clinical trials and be approved by FDA.
|
|